MedPath

AegisCN LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

A Proof of Concept Study to Evaluate CN-105 in ICH Patients

Phase 2
Completed
Conditions
Intracerebral Hemorrhage
Interventions
First Posted Date
2017-05-30
Last Posted Date
2020-03-11
Lead Sponsor
AegisCN LLC
Target Recruit Count
38
Registration Number
NCT03168581
Locations
🇺🇸

A.B. Chandler Medical Center-University of Kentucky, Lexington, Kentucky, United States

🇺🇸

Duke University Health System, Durham, North Carolina, United States

🇺🇸

Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

and more 2 locations

Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage

Phase 1
Completed
Conditions
Intracerebral Hemorrhage (ICH)
Interventions
Drug: Placebo
First Posted Date
2016-02-02
Last Posted Date
2016-08-18
Lead Sponsor
AegisCN LLC
Target Recruit Count
48
Registration Number
NCT02670824
Locations
🇺🇸

Duke Clinical Research Institute, Durham, North Carolina, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.